About us
Founded in 2012 and granted the qualification of biomedicine company by the Ministry of Economic Affairs in 2015, Energenesis Biomedical Co., Ltd. aspires to become a new star in biotech industry.
Information
- 2025-07 Energenesis Biomedical Announces Positive Phase I Results for ENERGI-F705PD, a Potential Disease-Modifying Treatment for Parkinson’s Disease
- 2025-03 Energenesis Biomedical and Medvisis Switzerland AG Sign MOU for F703DFU Commercialization in Switzerland
- 2025-03 Energenesis Biomedical and Phison Sign MOU to Advance AI-Driven Drug Development
- 2024-12 Energenesis Biomedical Co., Ltd. has signed a Memorandum of Understanding (MOU) with DEBRA Research gGmbH to collaborate on the development of F703EB.
- 2024-12 Energenesis Biomedical has received CRO notification that its Phase I IND application for "ENERGI-F705PD," an oral Parkinson's treatment, has been conditionally approved by the Ministry of Health and Welfare to begin clinical trials.